Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TLR9 Agonists Oppositely Modulate DNA Repair Genes in Tumor versus Immune Cells and Enhance Chemotherapy Effects

30 Aug 2011

Abstract excerpt

Synthetic oligodeoxynucleotides expressing CpG motifs (CpG-ODN) are a Toll-like receptor 9 (TLR9) agonist that can enhance the antitumor activity of DNA-damaging chemotherapy and radiation therapy in preclinical mouse models. We hypothesized that the success of these combinations is related to the ability of CpG-ODN to modulate genes involved in DNA repair. We conducted an in silico analysis of genes implicated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Immune Response and Inflammation
Share to Neonatal Respiratory Health Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21878529
DOI: 10.1158/0008-5472.can-11-1285

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TLR9 Agonists Oppositely Modulate DNA Repair Genes in Tumor versus Immune Cells and Enhance Chemotherapy EffectsPMID 21878529Read ↗

Role of TLR9 in Oncogenic Virus-Produced CancerSemantic proximity Read ↗

Enhancing radiotherapy response via intratumoral injection of the TLR9 agonist CpG to stimulate CD8 T cells in an autochthonous mouse model of sarcomaSemantic proximity Read ↗

CpG Oligodeoxynucleotides as TLR9 AgonistsSemantic proximity Read ↗

A Review of the Role of CpG Oligodeoxynucleotides as Toll-Like Receptor 9 Agonists in Prophylactic and Therapeutic Vaccine Development in Infectious DiseasesSemantic proximity Read ↗

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicrySemantic proximity Read ↗

Antiinfective Applications of Toll-like Receptor 9 AgonistsSemantic proximity Read ↗

New insights into the responder/nonresponder divide in rectal cancer: Damage-induced Type I IFNs dictate treatment efficacy and can be targeted to enhance radiotherapySemantic proximity Read ↗

TLR9 in health and disease.Semantic proximity Read ↗

Reversing Radiation-Induced Immunosuppression Using a New Therapeutic ModalitySemantic proximity Read ↗

Toll‐like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumorsSemantic proximity Read ↗

Recent Findings on the Application of Toll-like Receptors Agonists in Cancer TherapySemantic proximity Read ↗

Recognition of CpG oligodeoxynucleotides by human Toll-like receptor 9 and subsequent cytokine induction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.